drugset / Trial / NCT00921063

A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

NCT00921063

Phase 2 Completed 222 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of PD 0332334 compared to placebo in the treatment of Generalized Anxiety Disorder in an adult population

Timeline

Start
2005-11
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 1 mg
Subject IMAGABALIN Other / unclassified 100 mg
Subject IMAGABALIN Other / unclassified 250 mg